|1.||Serganova, Inna: 4 articles (08/2009 - 09/2004)|
|2.||Alauddin, Mian: 3 articles (10/2011 - 05/2007)|
|3.||Soghomonyan, Suren: 3 articles (01/2011 - 09/2004)|
|4.||Alauddin, Mian M: 3 articles (01/2011 - 01/2007)|
|5.||Gelovani, Juri G: 3 articles (01/2011 - 01/2007)|
|6.||Gelovani, Juri: 3 articles (08/2009 - 09/2004)|
|7.||Blasberg, Ronald: 3 articles (08/2009 - 09/2004)|
|8.||Doubrovin, Michael: 3 articles (08/2009 - 09/2004)|
|9.||Cai, Shangde: 3 articles (04/2008 - 09/2004)|
|10.||Conti, Peter S: 2 articles (07/2011 - 06/2007)|
01/01/2009 - "Presence of virus-infected tumor cells was successfully imaged with [(18)F]FEAU-PET, that identified 8 out of 8 tumor-positive nodes. "
01/01/2009 - "The presence of tumor-targeting and reporter-expressing virus was assessed by [(18)F]-2'-fluoro-2'-deoxy-1-beta-D-beta-arabinofuranosyl-5-ethyluracil ([(18)F]FEAU) positron emission tomography (PET) and confirmed by histochemical assays. "
04/15/2008 - "A linear correlation was shown between the number of viable bacteria in tumors and the accumulation of [18F]FEAU, but not [18F]FDG. "
04/15/2008 - "Imaging with [18F]FDG provided lower contrast than [18F]FEAU due to high FDG accumulation in control (nontreated) tumors and surrounding tissues. "
06/01/2007 - "Uptake of [3H]FEAU in transduced tumors was 9.98+/-1.99, 5.0-fold higher (p<0.001) than in wild type tumors. "
|2.||Sarcoma (Soft Tissue Sarcoma)
10/01/2011 - "This study characterized 1-(2'-deoxy-2'-[(18)F]fluoro-β-D-arabinofuranosyl)-5-iodocytosine ((18)F-FIAC) as a new potential positron emission tomography (PET) probe for HSV1-tk gene imaging and compared it with 2'-deoxy-2'-[(18)F]fluoro-5-iodo-1-β-D-arabinofuranosyluracil ((18)F-FIAU) and 2'-deoxy-2'-[(18)F]fluoro-5-ethyl-1-β-D-arabinofuranosyluracil((18)F-FEAU) (thymidine analogues) in an NG4TL4-WT/STK sarcoma-bearing mouse model. "
05/01/1987 - "While FEAU showed activity comparable to that of ACV in the systemic infection model, it was superior in the cutaneous herpes infection model."
04/01/1990 - "1-(2-Deoxy-2-fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) has been shown to be a highly effective inhibitor of Simian varicella virus infection in African green monkeys. "
01/01/2010 - "Further, the considerably higher potency of FEAU (2'-fluoro-5-ethyl-Ara-U) than of conventional antiviral drugs argues for its compassionate use in advanced human B virus infections."
04/01/1990 - "Inhibition of simian varicella virus infection of monkeys by 1-(2-deoxy-2- fluoro-1-beta-D-arabinofuranosyl)-5-ethyluracil (FEAU) and synergistic effects of combination with human recombinant interferon-beta."
05/01/1987 - "The in vivo antiviral effects of FEAU, FMAU, FIAU, and ACV were evaluated against herpes infection in a systemic mouse encephalitis model and a cutaneous guinea pig model. "
|4.||Neoplasm Metastasis (Metastasis)
01/01/2009 - "A new approach for imaging SLN metastases using NV1023 and [(18)F]FEAU-PET was successful in a murine model. "
08/01/2009 - "The sites and expansion of metastases were visualized by bioluminescence imaging using a constitutive firefly luciferase reporter, while TGFbeta signaling in metastases was monitored by microPET imaging of HSV1-TK/GFP expression with [(18)F]FEAU and by a more sensitive and cost-effective bioluminescence reporter, based on nonsecreted Gaussia luciferase. "
|3.||Arabinofuranosyluracil (Ara U)
|4.||Transforming Growth Factor beta (TGF-beta)
|5.||Recombinant Interferon Type I
|8.||Antiviral Agents (Antivirals)
|10.||2'- fluoro- 2'- deoxy- 5- fluoroethyl- 1- beta- D- arabinofuranosyl uracil
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)